A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
Recruiting · NCT07181837 · Registry updated 2026-07-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome | Abnormalities, Multiple, Angelman syndrome, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Imprinting Disorders, central nervous system disorder, chromosomal disorder, hereditary disease, movement disorder, nervous system disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-24 | NCT07181837 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| MavriX Bio, LLC | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital | Boston | United States | 343 |
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |
| Rush University Medical Center | Chicago | United States | 283 |